Detail akcie Laboratory Corp online

Business Summary: Laboratory Corporation of America Holdings provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Laboratory Corporation of Amerc Holdings revenues increased 3% to $12.16B. Net income before extraordinary items decreased 62% to $379.2M. Revenues reflect DX segment increase of 2% to $9.42B, BLS segment increase of 3% to $2.77B. Net income was offset by DX segment income decrease of 21% to $1.59B, General corporate segment loss increase of 29% to $1.26B.